Full Text Journal Articles by
Author Andrea Necchi

Advertisement

Find full text journal articles






Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.

Armando Stabile, Antony Pellegrino, Elio Mazzone, Donato Cannoletta, Mario de Angelis, Francesco Barletta, Simone Scuderi, Vito Cucchiara, Giorgio Gandaglia, Daniele Raggi, Andrea Necchi, Pierre Karakiewicz, Francesco Montorsi, Alberto Briganti,

<h4>Context</h4>The role of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate cancer (PCa) is still debated.<h4>Objective</h4>To analyze published studies reporting the accuracy of PSMA PET/CT for detecting lymph node invasion (LNI) at pelvic lymph node dissection (PLND).<h4>Evidence acquisition</h4>A search of ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin. Letter.

Francesco Montorsi, Marco Moschini, Andrea Necchi, Federico Deho, Giorgio Gandaglia, Alberto Briganti,

J Urol (The Journal of urology)
[2021, :101097JU0000000000002237]

Cited: 0 times

View full text PDF listing >>



Advertisement

Causal contributors to tissue stiffness and clinical relevance in urology.

Laura Martinez-Vidal, Valentina Murdica, Chiara Venegoni, Filippo Pederzoli, Marco Bandini, Andrea Necchi, Andrea Salonia, Massimo Alfano,

Mechanomedicine is an emerging field focused on characterizing mechanical changes in cells and tissues coupled with a specific disease. Understanding the mechanical cues that drive disease progression, and whether tissue stiffening can precede disease development, is crucial in order to define new mechanical biomarkers to improve and develop diagnostic and ... Read more >>

Commun Biol (Communications biology)
[2021, 4(1):1011]

Cited: 0 times

View full text PDF listing >>



Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition.

Andrea Necchi, Daniele Raggi, Andrea Gallina, Marco Bandini, Joep J de Jong, Laura Marandino, Alberto Briganti, Francesco Montorsi, Elai Davicioni, Yair Lotan, Ewan A Gibb,

<h4>Purpose</h4>Clinical high-grade (HG) T1 non-muscle invasive bladder cancer (NMIBC) represents a significant risk to patients, but these patients are not typically offered neoadjuvant therapies, including immune therapy. In this study, we determine whether patients with HG clinical T1 or T2 bladder urothelial carcinoma (UC) have profiles that predict the potential ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration.

Chiara Lonati, Philipp Baumeister, Luca Afferi, Andrea Mari, Andrea Minervini, Wojciech Krajewski, Sosan Azizi, Kees Hendricksen, Alberto Martini, Andrea Necchi, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Alessandro Tafuri, Alessandro Antonelli, Maria Angela Cerruto, Morgan Rouprêt, Alexandra Masson-Lecomte, Ekaterina Laukhtina, David D'Andrea, Shahrokh F Shariat, Francesco Soria, Giancarlo Marra, Paolo Gontero, Roberto Contieri, Rodolfo Hurle, Anne Sophie Valiquette, M Carmen Mir, Stefania Zamboni, Claudio Simeone, Tobias Klatte, Jeremy Yuen-Chun Teoh, Soichiro Yoshida, Yasuhisa Fujii, Roberto Carando, Gerald B Schulz, Livio Mordasini, Agostino Mattei, Marco Moschini, ,

<h4>Background</h4>Literature lacks clear evidence regarding the optimal treatment for non-muscle-invasive micropapillary bladder cancer (MPBC) due to its rarity and the presence of only small sample size and single-centre studies.<h4>Objective</h4>To assess cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and conservative management among T1 high-grade (HG) MPBC.<h4>Design, ... Read more >>

Eur Urol Focus (European urology focus)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Reply by Authors.

Nicholas H Chakiryan, Aaron Dahmen, Marco Bandini, Filippo Pederzoli, Laura Marandino, Maarten Albersen, Eduard Roussel, Yao Zhu, Ding-Wei Ye, Antonio A Ornellas, Mario Catanzaro, Oliver W Hakenberg, Axel Heidenreich, Friederike Haidl, Nick Watkin, Michael Ager, Jad Chahoud, Alberto Briganti, Roberto Salvioni, Francesco Montorsi, Andrea Necchi, Philippe E Spiess,

J Urol (The Journal of urology)
[2021, 206(4):969]

Cited: 0 times

View full text PDF listing >>



Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.

Catherine Curran, Elio Adib, Vera Kazakova, Petros Grivas, Leonidas Nikolaos Diamantopoulos, Ajjai Shivaram Alva, Christopher Su, Rohit K Jain, Ankita Tandon, Andrea Necchi, Laura Marandino, Trisha M Plastini, Jaime R Merchan, Guru Sonpavde,

<h4>Background</h4>Enfortumab vedotin (EV) is approved to treat metastatic urothelial carcinoma (mUC) following platinum and PD1/L1 inhibitors. Since the outcomes and patterns of therapy of patients following discontinuation of EV are unknown, we conducted a retrospective study to assess this issue.<h4>Methods</h4>Data were retrospectively obtained from patients with mUC following discontinuation of ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.

Risa L Wong, Lorin A Ferris, Olivia A Do, Sarah K Holt, Jorge D Ramos, Simon J Crabb, Cora N Sternberg, Joaquim Bellmunt, Sylvain Ladoire, Ugo De Giorgi, Lauren C Harshman, Ulka N Vaishampayan, Andrea Necchi, Sandy Srinivas, Sumanta K Pal, Guenter Niegisch, Tanya B Dorff, Matthew D Galsky, Evan Y Yu,

<h4>Background</h4>Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may receive additional later-line chemotherapy after progression. Our study compares outcomes with subsequent platinum-based chemotherapy (sPBC) versus subsequent non-platinum-based chemotherapy (sNPBC).<h4>Materials and methods</h4>Patients from 27 international centers in the Retrospective International Study ... Read more >>

Oncologist (The oncologist)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.

Andrea Necchi, Vito Cucchiara, Petros Grivas, Gennady Bratslavsky, Joseph Jacob, Philippe E Spiess, Ethan S Sokol, Jonathan Keith Killian, Douglas Lin, Shakti Ramkissoon, Richard S P Huang, Russell W Madison, Jeffrey M Venstrom, Alexa B Schrock, Natalie Danziger, Brennan Decker, Ole Gjoerup, Ryon P Graf, Geoffrey R Oxnard, Hanna Tukachinsky, Jeffrey S Ross,

<h4>Background</h4>This study assessed the contrasting genomic profiles from the primary tumors (PTs), metastatic (MET) sites, and circulating tumor DNA (ctDNA) of patients with prostate cancer (PC).<h4>Methods</h4>A total of 1294 PC tissue specimens and 2462 ctDNA specimens underwent hybrid capture-based comprehensive genomic profiling (CGP). Specimens included tissue from PTs; MET biopsies ... Read more >>

Cancer (Cancer)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study.

Gennady Bratslavsky, Ethan S Sokol, Michael Daneshvar, Andrea Necchi, Oleg Shapiro, Joseph Jacob, Nick Liu, Tom S Sanford, Ruben Pinkhasov, Hanan Goldberg, Jonathan K Killian, Shakti Ramkissoon, Eric A Severson, Richard S P Huang, Natalie Danziger, Mehdi Mollapour, Jeffrey S Ross, Karel Pacak,

Patients with clinically advanced paragangliomas (CA-Para) and pheochromocytomas (CA-Pheo) have limited surgical or systemic treatments. We used comprehensive genomic profiling (CGP) to compare genomic alterations (GA) in CA-Para and CA-Pheo to identify potential therapeutic targets. Eighty-three CA-Para and 45 CA-Pheo underwent hybrid-capture-based CGP using a targeted panel of 324 genes. ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(13):]

Cited: 0 times

View full text PDF listing >>



A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation.

Michele Maio, Michael Lahn, Anna Maria Di Giacomo, Alessia Covre, Luana Calabrò, Ramy Ibrahim, Bernard Fox, ,

<h4>Background</h4>The yearly Think Tank Meeting of the Italian Network for Tumor Biotherapy (NIBIT) Foundation, brings together in Siena, Tuscany (Italy), experts in immuno-oncology to review the learnings from current immunotherapy treatments, and to propose new pre-clinical and clinical investigations in selected research areas. MAIN: While immunotherapies in non-small cell lung ... Read more >>

J Exp Clin Cancer Res (Journal of experimental & clinical cancer research : CR)
[2021, 40(1):240]

Cited: 0 times

View full text PDF listing >>



Primary Renal Tumour Response to Immunotherapy: Lessons from Metastatic Disease and Insights into Earlier Settings.

Laura Marandino, Andrea Necchi,

Eur Urol (European urology)
[2021, 80(3):330-332]

Cited: 0 times

View full text PDF listing >>



A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02.

Andrea Necchi, Alberto Martini, Daniele Raggi, Vito Cucchiara, Maurizio Colecchia, Roberta Lucianò, Luca Villa, Elio Mazzone, Giuseppe Basile, Simone Scuderi, Filippo Pederzoli, Marco Bandini, Francesco Barletta, Alessandro Larcher, Umberto Capitanio, Andrea Salonia, Alberto Briganti, Jeffrey S Ross, Antonella Messina, Francesco Montorsi,

<h4>Introduction</h4>Advances in neoadjuvant therapy for patients with localized, nonmetastatic, upper tract urothelial carcinoma (UTUC) is needed.<h4>Patients and methods</h4>PURE-02 was a feasibility study enrolling individuals with UTUC, at clinical stage N0M0, with high-risk features according to the modified European Association of Urology definition, based on the presence of either: high-grade disease, ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?

Giuseppe Fallara, Marco Bandini, Alessandro Larcher, Filippo Pederzoli, Pierre Karakiewicz, Zhe Tian, Alberto Briganti, Andrea Necchi, Andrea Salonia, Roberto Bertini, Francesco Montorsi, Axel Bex, Umberto Capitanio,

The indications for adjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) agents after curative intent nephrectomy for renal cell carcinoma are still a matter of debate. The ASSURE, PROTECT and ATLAS trials have failed to meet their primary end-points. Conversely, S-TRAC has shown a disease free survival (DFS) benefit. To ... Read more >>

Curr Probl Cancer (Current problems in cancer)
[2021, :100759]

Cited: 0 times

View full text PDF listing >>



Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).

Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, Marco Bandini, Giuseppe Luigi Banna, Filippo Pederzoli, Elena Farè, Daniele Raggi, Patrizia Giannatempo, Ugo De Giorgi, Umberto Basso, Tania Losanno, Daniele Santini, Claudia Mucciarini, Marcello Tucci, Rosa Tambaro, Azzurra Farnesi, Orazio Caffo, Antonello Veccia, Emanuele Naglieri, Alberto Briganti, Giuseppe Procopio, Sandro Pignata, Andrea Necchi,

<h4>Background</h4>Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine the outcomes of mUC patients after progression ... Read more >>

Clin Med Insights Oncol (Clinical Medicine Insights. Oncology)
[2021, 15:11795549211021667]

Cited: 0 times

View full text PDF listing >>



The obesity paradox in metastatic castration-resistant prostate cancer.

Alberto Martini, Qainat N Shah, Nikhil Waingankar, John P Sfakianos, Che-Kai Tsao, Andrea Necchi, Francesco Montorsi, Emily J Gallagher, Matthew D Galsky,

<h4>Objective</h4>To test whether body mass index (BMI) amongst patients with metastatic castration-resistant prostate cancer (mCRPC) is associated with overall survival (OS) and cancer-specific survival.<h4>Methods</h4>Individual patient data from 1577 men with mCRPC treated with docetaxel and prednisone from the control arms of ASCENT2, VENICE, and MAINSAIL were considered. The role of ... Read more >>

Prostate Cancer Prostatic Dis (Prostate cancer and prostatic diseases)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Comprehensive genomic profiling of histologic subtypes of urethral carcinomas.

Joseph Jacob, Andrea Necchi, Petros Grivas, Michael Hughes, Thomas Sanford, Mehdi Mollapour, Oleg Shapiro, Ahmad Talal, Ethan Sokol, Jo-Anne Vergilio, Jonathan Killian, Douglas Lin, Erik Williams, Julie Tse, Shakti Ramkissoon, Eric Severson, Amanda Hemmerich, Naomi Ferguson, Clair Edgerly, Daniel Duncan, Richard Huang, Jon Chung, Russell Madison, Brian Alexander, Jeffrey Venstrom, Prasanth Reddy, Kimberly McGregor, Julia Elvin, Alexa Schrock, Natalie Danziger, Dean Pavlick, Jeffrey Ross, Gennady Bratslavsky,

<h4>Background</h4>Carcinoma of the urethra (UrthCa) is an uncommon Genitourinary (GU) malignancy that can progress to advanced metastatic disease.<h4>Methods</h4>One hundred twenty-seven metastatic UrthCa underwent hybrid capture-based comprehensive genomic profiling to evaluate all classes of genomic alterations (GA). Tumor mutational burden was determined on up to 1.1 Mbp of sequenced DNA, and ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer.

Daniele Raggi, Marco Moschini, Andrea Necchi,

Cisplatin-based chemotherapy followed by radical cystectomy with bilateral pelvic lymph-node dissection is the current standard for cT2-4a N0 M0 urothelial bladder cancer. Immune checkpoint inhibitors have recently been tested in the neoadjuvant setting with promising pathological and survival results and a better safety profile. Excellent pathological responses have been observed, ... Read more >>

Eur Urol Open Sci (European urology open science)
[2021, 30:34-36]

Cited: 0 times

View full text PDF listing >>



Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review.

Fernando Korkes, Phillipe E Spiess, Herney Andres Garcia-Perdomo, Andrea Necchi,

<h4>Purpose</h4>To describe the current scientific knowledge and clinical experience in low-grade-non-muscle-invasive bladder cancer (LG-NMIBC) patients in challenging scenarios.<h4>Materials and methods</h4>Medline, Embase, Google Scholar, and Cochrane Central were searched until March 2021.<h4>Results</h4>A total of 841 studies were identified, and abstracts were analyzed. Twenty-one relevant studies were then identified and reviewed. After ... Read more >>

Int Braz J Urol (International braz j urol : official journal of the Brazilian Society of Urology)
[2021, 47:]

Cited: 0 times

View full text PDF listing >>



Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer.

Gianluca Giannarini, Neeraj Agarwal, Andrea B Apolo, Alberto Briganti, Petros Grivas, Shilpa Gupta, Ashish M Kamat, Francesco Montorsi, Morgan Rouprêt, Andrea Necchi,

Novel immune checkpoint inhibitors hold promise for non-muscle-invasive bladder cancer. Cooperation between urologists and other multidisciplinary bladder cancer specialists can surmount the challenges involved in using these agents in bladder-sparing approaches. This strategy could deliver a new era of comprehensive evaluation and multimodal treatment for this patient population. ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities.

M Carmen Mir, Riccardo Campi, Yohann Loriot, Javier Puente, Gianluca Giannarini, Andrea Necchi, Morgan Rouprêt, ,

We describe the case of a 71-yr-old woman with locally advanced muscle-invasive bladder cancer and stage III chronic kidney disease due to an obstructed nonfunctional left kidney. She was started on neoadjuvant immunotherapy, but had to stop treatment because of acute worsening of renal function. Radical cystectomy was then performed ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

Michele Maio, Christian Blank, Andrea Necchi, Anna Maria Di Giacomo, Ramy Ibrahim, Michael Lahn, Bernard A Fox, R Bryan Bell, Giampaolo Tortora, Alexander M M Eggermont,

The Italian Network for Tumor Biotherapy (Network Italiano per la Bioterapia dei Tumori [NIBIT]) Foundation hosted its annual 2020 Think Tank meeting virtually, at which representatives from academic, clinical, industry, philanthropic, and regulatory organisations discussed the role of neoadjuvant immunotherapy for the treatment of cancer. Although the number of neoadjuvant immunotherapeutic ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 152:155-164]

Cited: 1 time

View full text PDF listing >>



Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.

Matthew D Galsky, Christopher J Hoimes, Andrea Necchi, Neal Shore, J Alfred Witjes, Gary Steinberg, Jens Bedke, Hiroyuki Nishiyama, Xiao Fang, Ritesh Kataria, Eric Sbar, Xieyang Jia, Arlene Siefker-Radtke,

Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite aggressive treatment. Neoadjuvant chemotherapy before radical cystectomy (RC) improves outcomes in cisplatin-eligible patients; however, the improvement in overall survival is modest. Standard of care for cisplatin-ineligible patients remains RC; more effective systemic therapies are needed. Recent ... Read more >>

Future Oncol (Future oncology (London, England))
[2021, 17(24):3137-3150]

Cited: 0 times

View full text PDF listing >>



Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies.

Nicholas H Chakiryan, Aaron Dahmen, Marco Bandini, Filippo Pederzoli, Laura Marandino, Maarten Albersen, Eduard Roussel, Yao Zhu, Ding-Wei Ye, Antonio A Ornellas, Mario Catanzaro, Oliver W Hakenberg, Axel Heidenreich, Friederike Haidl, Nick Watkin, Michael Ager, Jad Chahoud, Alberto Briganti, Roberto Salvioni, Francesco Montorsi, Andrea Necchi, Philippe E Spiess,

<h4>Purpose</h4>Our primary objective is to detail the incidence, site, and timing of penile squamous cell carcinoma (pSCC) recurrence after inguinal lymph node dissection (ILND).<h4>Materials and methods</h4>We performed a retrospective analysis of 551 patients who underwent ILND for pSCC from 2000 to 2017. The primary outcome was pSCC recurrence after ILND. ... Read more >>

J Urol (The Journal of urology)
[2021, 206(4):960-969]

Cited: 0 times

View full text PDF listing >>



Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?

Filippo Pederzoli, Marco Bandini, Daniele Raggi, Laura Marandino, Giuseppe Basile, Massimo Alfano, Renzo Colombo, Andrea Salonia, Alberto Briganti, Andrea Gallina, Francesco Montorsi, Andrea Necchi,

In locally advanced and metastatic malignancies, antibiotic (ATB) therapy has a negative effect on immunotherapy efficacy. Therefore, we aimed to evaluate whether ATB therapy and use of specific ATB classes with concomitant neoadjuvant pembrolizumab affected pathologic complete response (ypT0N0) and relapse-free survival (RFS) for patients with clinical T2-4N0M0 bladder cancer ... Read more >>

Eur Urol (European urology)
[2021, 80(3):319-322]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.172 s